左芬氟拉明
左芬氟拉明结构式
|
常用名 | 左芬氟拉明 | 英文名 | (R)-fenfluramine |
|---|---|---|---|---|
| CAS号 | 37577-24-5 | 分子量 | 267.71800 | |
| 密度 | 1.078g/cm3 | 沸点 | 243.1ºC at 760mmHg | |
| 分子式 | C12H17ClF3N | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 100.8ºC | |
| 符号 |
GHS06 |
信号词 | Danger |
|
[Phentermine--a "weighty" or a dangerous substance?].
Arch. Kriminol. 231(3-4) , 116-29, (2013) According to international surveys, the appetite suppressant phentermine has frequently been seized although its approval has been withdrawn in Germany. Phentermine is an isomer of methamphetamine though is not optically active such as e. g. amphetamine. The ... |
|
|
Rapid screening of illicit additives in weight loss dietary supplements with desorption corona beam ionisation (DCBI) mass spectrometry.
Food Addit. Contam. Part A. Chem. Anal. Control. Expo. Risk Assess. 29(8) , 1194-201, (2012) Desorption corona beam ionisation (DCBI), the relatively novel ambient mass spectrometry (MS) technique, was utilised to screen for illicit additives in weight-loss food. The five usually abused chemicals - fenfluramine, N-di-desmethyl sibutramine, N-mono-des... |
|
|
Biphasic mechanisms of amphetamine action at the dopamine terminal.
J. Neurosci. 34(16) , 5575-82, (2014) In light of recent studies suggesting that amphetamine (AMPH) increases electrically evoked dopamine release ([DA]o), we examined discrepancies between these findings and literature that has demonstrated AMPH-induced decreases in [DA]o. The current study has ... |
|
|
Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment.
Behav. Pharmacol. 24(5-6) , 448-58, (2013) 'Rate dependency' in the discipline of behavioral pharmacology describes a phenomenon wherein the effect of a drug on the rate of a behavior varies systematically as a function of the baseline, predrug rate of that behavior. Historically, rate-dependency stud... |
|
|
Toxicity of weight loss agents.
J. Med. Toxicol. 8(2) , 145-52, (2012) With the rise of the obesity epidemic in the United States over the last several decades and the medical complications seen with it, weight loss and dieting have become a national public health concern.Because of their increased use and availability through i... |
|
|
[About the settlement of litigations concerning the harm caused by benfluorex (Mediator®)].
Presse Med. 42(4 Pt 1) , 411-8, (2013) Since September 1st 2011, the National Bureau for Compensation of Medical Accidents represents a unique portal for out-of-court settlement of litigations concerning the harm caused by benfluorex. In December 2012, its official record is as follows: 7627 patie... |
|
|
[Reform Act on safety of drug and health products in France: announcement effect, strengthening or upheaval?].
Therapie. 67(1) , 1-10, (2012) In France, the Médiator(®) scandal and the trauma it has created, are the source of Law n° 2011-2012 of 29 December 2011 on strengthening safety of drug and health products, intended by the Ministry of Labour, Employment and Health, adopted by the National As... |
|
|
Mediator scandal engulfs French compensation body.
Lancet 381(9880) , 1803, (2013)
|
|
|
European legislators tighten rules on drug safety.
BMJ 345 , e6260, (2012)
|
|
|
Can benfluorex induce congenital malformations?
Diabetes Metab. 38(4) , 373-4, (2012)
|